Gapping up
In reaction to strong earnings/guidance: DRI +4.5%
M&A news: ARLZ +12.1% (acquires AstraZeneca's (AZN) rights to Toprol-XL; expected to be EBITDA accretive and to move profitability forward to 2017), .
Select metals/mining stocks trading higher: MT +2%, RIO +1.9%, BHP +1.7%, BBL +1.6%
Select oil/gas related names showing strength: RDS.A +1.6%, BP +1.4%, BT +1%, TOT +1%
Other news:
In reaction to strong earnings/guidance: DRI +4.5%
M&A news: ARLZ +12.1% (acquires AstraZeneca's (AZN) rights to Toprol-XL; expected to be EBITDA accretive and to move profitability forward to 2017), .
Select metals/mining stocks trading higher: MT +2%, RIO +1.9%, BHP +1.7%, BBL +1.6%
Select oil/gas related names showing strength: RDS.A +1.6%, BP +1.4%, BT +1%, TOT +1%
Other news:
- SDRL +33% (attributed to report that 23% shareholder John Fredriksen could provide a loan to help co restructure debt)
- CNAT +8.7% (higher in after hours after announcing acceptance of emricasan abstracts for AASLD Annual Meeting November 11-15)
- SDLP +6.6% (rising with SDRL)
- OLLI +5.2% (to join S&P SmallCap 600)
- XGTI +5.1% (following 65% move higher on Monday)
- PKY +5% (to join S&P SmallCap 600)
- BIOD +3.4% (ticking higher, Biodel confirms Albireo announced positive top-line results from a pivotal Ph 3 clinical trial of its product candidate, elobixibat, in chronic constipation conducted in Japan)
- VHC +1.2% (after 30% move higher on Apple news)
- GSK +1% (still checking)
- TASR +0.9% (announces the receipt of an order for a total of 900 TASERX2 Smart Weapons for the Kentucky State Police)
Analyst comments:
- SHOP +3.4% (initiated with a Buy at Goldman)
- P +3.4% (added to Conviction Buy List at Goldman)
- VSAR +2.8% (initiated with a Overweight at Piper Jaffray)
- RIG +2.3% (upgraded to Sector Outperform at Scotia Howard Weil)
- CBOE +1.6% (upgraded to Outperform from Market Perform at Wells Fargo)
- LVS +1.6% (upgraded to Buy from Neutral at BofA/Merrill)